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Interfakultäres Institut für Mikrobiologie und Infektionsmedizin, Univ. Tübingen, GermanyTable 2
Number of articles submitted to Journal of Cystic Fibrosis, processing times,
results of articles and rejection rate from 2006 to 2009.
Year
2006 2007 2008 2009
Submission
# of articles 135 175 184 194
Final disposition
# of articles 141 149 211 192
Processing times
Submission to first decision (weeks) 9.8 7.6 7.3 4.3
Author revision time (weeks) 6.6 6.6 6.4 7.2
Submission to final disposition (weeks) 15.4 13.3 16.6 8.4
Results
Withdrawn 0 0 17 0The Journal of Cystic Fibrosis is the official Journal of the
European Cystic Fibrosis Society (ECFS). The ECFS is a
professional organisation and has members that form a wide
range of disciplines including scientists, physicians, nurses and
allied health professionals. The mission of ECFS is to facilitate
the acquisition and sharing of knowledge and the improvement
of patient care in all aspects of CF. An important instrument for
this mission is the Journal. After nearly a decade, the Journal is
now a well established source of valuable scientific and clinical
information for individuals all over the world, interested in this
hereditary disease. Cystic Fibrosis is a very complex disease
which is mirrored by the high diversity of topics which are
covered in the Journal (Table 1). Articles are published online
and in the six yearly issues of the Journal or supplements.E-mail address: gerd.doering@med.uni-tuebingen.de.
1 Editor-in-Chief of the Journal of Cystic Fibrosis and Head of Cystic Fibrosis
Research Group.
Table 1
Topics related to cystic fibrosis in alphabetical order, published by the Journal.
Airway clearance Hygiene Pharmacokinetics
Airway resistance Immunodeficiency Physiotherapy
Anorexia Inflammation Pulmonary infections
Antibiotic therapy Inhalation Pseudomonas
Biofilms Jaundice Psychosocial aspects
Burkholderia Kidney Pulmonary function
Carrier frequency Late diagnosis Registry
CETR gene Life expectancy Renal dysfunction
Compliance Magnetic resonance Reproductive health
Contraception Mechanical ventilation Respiratory function
Controlled Trials Membrane potential Self-management
Diabetes Microbiology Spirometry
Diet Molecular biology Sputum analysis
Drug delivery Mucociliary clearance Staphylococcus
Enteral feeding Mucus rheology Surveillance
Eradication treatment Mutations Sweat test
Failure to Thrive Nebulised antibiotics Urinary biomarkers
Fertility Neonatal screening Vitamin deficiency
FEV 1 Nutrition Yeasts
Accepted 74 70 71 60
Rejected 67 79 123 132
Rejection rate (%) 48 53 58 69
Fig. 1. Editorial time, web production and print production times of the Journal
of Cystic Fibrosis during 2006 to 2009.
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156 G. Döring / Journal of Cystic Fibrosis 9 (2010) 155–157The number of articles submitted to the Journal has
increased year-on-year, with 2009 seeing almost 200 articles
(Table 2). Manuscripts, submitted via the Elsevier web based
electronic submission system ees, have reached a handling time
from first submission to first decision by the Editorial Office in
2009 of 4.3 weeks (Table 3). In 2009, we have reached a
rejection rate of 69%, which may in part result from the
possibility that many contributors are not fully aware of theTable 3
Top 10 cited articles published in the last five years. Extracted from Scopus.
Author Title
Southern KW, et al. A survey of newborn screening for cystic fibrosis in E
Castellani C, et al. Consensus on the use and interpretation of cystic fibr
Yim S, et al. Induction of cathelicidin in normal and CF bronchial
Bellis G, et al. Cystic fibrosis mortality trends in France
Westerman EM, et al. Dry powder inhalation of colistin in cystic fibrosis pa
Hansen CR, et al. Early aggressive eradication therapy for intermittent P
cystic fibrosis patients: 15 years experience
De Baets F, et al. Achromobacter xylosoxidans in cystic fibrosis: Preval
Costa M, et al. Increased glucose excursion in cystic fibrosis and its
Moran J, et al. Newborn screening for CF in a regional paediatric ce
IRT results on parents
Fennell PB, et al. Use of high-dose ibuprofen in a pediatric cystic fibro
Kerem E, et al. Standards of care for patients with cystic fibrosis: A E
Høiby N, et al. Eradication of early Pseudomonas aeruginosa infectio
Castellani C et al. Consensus on the use and interpretation of CFmutatio
Hansen CR, et al. Long-term azitromycin treatment of cystic fibrosis pa
infection; an observational cohort study
Steinkamp G, et al. Prospective evaluation of emerging bacteria in cystic
Modi AC, et al. A multi-method assessment of treatment adherence fo
Yim S, et al. Induction of cathelicidin in normal and CF bronchial
Hilliard T, et al. Voriconazole therapy in children with cystic fibrosis
Bellis G, et al. Cystic fibrosis mortality trends in France
X?
Table 4
Top 10 most downloaded articles. Extracted from ScienceDirect.
Author Title
1 Conese M & Rejman J. Stem cells and cystic fibrosis
2 Pfeffer PE et al. The psychosocial and psychiatric side of cys
3 Castellani C et al. Consensus on the use and interpretation of cy
4 Kerem E, et al. Standards of care for patients with cystic fibr
5 Li H, et al. Transepithelial electrical measurements with
6 Heijerman H. Infection and inflammation in cystic fibrosis:
7 Kamin W, et al. Inhalation solutions— which one are allowe
solutions in nebulizers
8 Arias Llorente RP, et al. Treatment compliance in children and adults
9 Ameen N, et al. Endocytic trafficking of CFTR in health and
10 Høiby N, et al. Eradication of early Pseudomonas aeruginosquality that we expect for the Journal. Also editorial times, web
production and print production times decreased from 2006
to 2009 (Fig. 1). In 2009, JCF took on average 18.5 weeks
to process papers and submit them in-house to Elsevier
production. Once with Elsevier they took a further
15.7 weeks before being printed. The average total time from
submission by an author to publication online was 34.2 weeks
(Table 4).J Cyst Fibros
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157G. Döring / Journal of Cystic Fibrosis 9 (2010) 155–157Authors who publish in the Journal are based geographically
mostly in Western Europe, followed closely by the United
States and Canada (Fig. 2). An increasing number of individuals
visit JCF online with more than 120,000 in 2009 (Fig. 3).
Accepted for Medline in 2004, the Journal received an ImpactFig. 3. Online audience of the Journal of Cystic Fibrosis from 2006 to 2009.
Fig. 4. Impact factor and cited half life of published articles in the Journal of
Cystic Fibrosis.
Fig. 2. Geographical basis of authors who publish in tFactor of 1.55 in 2009 by the Thomson Corporation as esteem
of the Journal's scientific quality (Fig. 4). This will undoubtedly
make JCF even more attractive and we expect that number of
manuscripts which we will receive in the next years will further
increase.he Journal of Cystic Fibrosis from 2006 to 2009.Without my assistant, Marie-Luise Grauer, the support of the
European Cystic Fibrosis Society and the hard work within
Elsevier, these results could not have been achieved. It is a
pleasure to serve as Editor-in-Chief for the Journal and I would
like to express my sincere thanks to the members of the
international Editorial Board, composed of well-known experts
in the field of cystic fibrosis who worked with me during my
first term from 2006 to 2010. Together we will try to maintain
our primary commitment to the scientific community, namely of
publishing high quality manuscripts that have been selected by a
fair, rapid and scientifically sound process, and of ensuring that
they have high visibility and availability to those who are
working in CF.
